Pharmaceutical

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH).
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (h...

Next Article

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The best AI opportunities, tech to improve 988, and an MRI fundraise

The best AI opportunities, tech to improve 988, and an ...

Jun 22, 2023

Innate Pharma plans IND of ADC candidate after positive preclinical data

Innate Pharma plans IND of ADC candidate after positive...

Apr 11, 2024

Pharma companies must adapt to keep pace with AI developments, say experts

Pharma companies must adapt to keep pace with AI develo...

Oct 26, 2024